Experimental combo aims to outsmart resistant prostate cancer
NCT ID NCT03480646
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested an experimental drug called CPI-1205 combined with standard hormone therapies (enzalutamide or abiraterone/prednisone) in 175 men with metastatic castration-resistant prostate cancer, a form of prostate cancer that has spread and stopped responding to usual hormone treatment. The goal was to find the best dose and see if the combination helps shrink tumors or lower PSA levels. The trial has completed, and results will show whether this approach is safe and worth further study.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CPI-1205 (an experimental drug) combined with enzalutamide or abiraterone/prednisone
What this could lead to
If it works, this could lead to a new combination treatment option for men with advanced prostate cancer that has stopped responding to standard hormone therapy.
What could go wrong
This is an early-phase trial (Phase 1b/2) with a small number of participants, so results may not apply to all patients. The experimental drug CPI-1205 may cause side effects or not improve outcomes enough to warrant further development.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Alaska Urological Institute
Anchorage, Alaska, 99503, United States
-
Beverly Hills Cancer Center (BHCC)
Beverly Hills, California, 90211, United States
-
Carolina Urologic Research Center
Myrtle Beach, South Carolina, 29572, United States
-
Compass Oncology - East
Tualatin, Oregon, 97062, United States
-
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada, 89135, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02115, United States
-
Duke University Medical Center
Durham, North Carolina, 22710, United States
-
Eastchester Center for Cancer Care
The Bronx, New York, 10469, United States
-
GU Research Network
Omaha, Nebraska, 68130, United States
-
Gettysburg Cancer Center
Gettysburg, Pennsylvania, 17331, United States
-
Greenville Hospital System, Institute for Translational Oncology Research
Greenville, South Carolina, 29605, United States
-
H. Lee Moffitt Cancer Center & Research Institute
Tampa, Florida, 33612, United States
-
Henry Ford Health System
Detroit, Michigan, 48202, United States
-
Icahn School of Medicine at Mt. Sinai
New York, New York, 10029, United States
-
Indiana University- Simon Cancer Center
Indianapolis, Indiana, 46202, United States
-
John Hopkins Kimmel Cancer Center
Baltimore, Maryland, 21205, United States
-
John Wayne Cancer Inst.
Duarte, California, 91010, United States
-
Levine Cancer Institute
Charlotte, North Carolina, 28204, United States
-
Maryland Oncology Hematology
Rockville, Maryland, 20850, United States
-
Mount Sinai Comprehensive Cancer Center
Miami, Florida, 33140, United States
-
NYU Langone Medical Center Laura and Isaac Permlutter Cancer Center
New York, New York, 10016, United States
-
New Mexico Cancer Center
Albuquerque, New Mexico, 87106, United States
-
North Shore Hematology Oncology Associates
East Setauket, New York, 11733, United States
-
Ohio State University - James Cancer Hospital and Solove Research Institute
Columbus, Ohio, 43210, United States
-
Rocky Mountain Cancer Centers
Aurora, Colorado, 80045, United States
-
Roswell Park Comprehensive Cancer Center
Buffalo, New York, 14263, United States
-
Rush University Medical Center
Chicago, Illinois, 60612, United States
-
St. Luke's University
Bethlehem, Pennsylvania, 18015, United States
-
Texas Oncology - Central Austin Cancer Center
Austin, Texas, 78731, United States
-
Texas Oncology- Fort Worth
Fort Worth, Texas, 76104, United States
-
Texas Oncology- Tyler
Tyler, Texas, 75702, United States
-
Toledo Clinic Cancer Center
Toledo, Ohio, 43623, United States
-
Tulane University Health Sciences Center
New Orleans, Louisiana, 70112, United States
-
UCLA
Los Angeles, California, 90095, United States
-
University of Colorado Hospital - Anschutz Cancer Pavilion
Aurora, Colorado, 80045, United States
-
University of Florida
Jacksonville, Florida, 32209, United States
-
University of Illinois Hospital and Health Systems
Chicago, Illinois, 60612, United States
-
University of Maryland
Baltimore, Maryland, 21201, United States
-
University of North Carolina-Chapel Hill
Chapel Hill, North Carolina, 27599, United States
-
Virginia Oncology Associates
Hampton, Virginia, 23666, United States
-
Williamette Valley Cancer Institute and Research Center
Eugene, Oregon, 97401, United States